Up a level |
Micaleff, Alain, Callreus, Tornbjorn, Phillips, Lawrence D., Hughes, Diana, Hockley, Kimberley, Wang, Nan and Luciani, David (2013) IMI work package 5: report 1:b:iii benefit - riskwave 1 case study report:Raptiva® (efalizumab). . PROTECT Consortium, London.